JPMORGAN props up CARL ZEISS MEDITEC AG to ‘Underweight’

NEW YORK (dpa-AFX Analyser) – The American bank JPMorgan (JPM) has executed the financing for Carl Zeiss Meditec with a price of 56 euros on “underweight” values. The paper of the medical technology appears on the stamp “Negative Catalyst Watch” due to the doubts about the quarterly report in mid-December. The big worry factor remains the outlook for the business year 2025, writes analyst David Adlington in one of the free time for industry commentary. The operative performance consensus is still apparently too independent. Adlington himself lies 12 percent there./ag/la

Veröffentlichung der Original-Studie: 12.09.2024 / 21:08 / BST First Weitergabe der Original-Studie: 13.09.2024 / 00:20 / BST

Note: Information about Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, art. 20 VO (EU) 596/2014 for the generated analyst house can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

The Carl Zeiss Meditec Promotion is aimed at a disadvantage at the time of sale -0.27 % and a course of 55.70EUR traded on Tradegate (September 13, 2024, 08:20 AM).